SCHEMBL2490988

SCHEMBL2490988

CCc1oc(-c2ccccc2)nc1C(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 6/20 0.59
ALDH1A1 P00352 8/20 0.54
KDM4E B2RXH2 4/20 0.54
HPGD P15428 3/20 0.54
HSD17B10 Q99714 2/20 0.54
KMT2A Q03164 2/20 0.54
TSHR P16473 1/20 0.54
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 2/20 0.48
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
STAT1 P42224 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3616364 0.84 TARBP2 (0.62) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL13007418 0.84 KDM4E (0.63) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2790948 0.82 TARBP2 (0.53) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL596762 0.81 TARBP2 (0.52) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3606475 0.81 TARBP2 (0.68) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL25309649 0.79 TARBP2 (0.53) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2486987 0.78 TARBP2 (0.68) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2823689 0.75 TARBP2 (0.75) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18003341 0.75 TARBP2 (0.76) TARBP2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3618601 0.75 ALDH1A1 (0.48) TARBP2ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211914-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-07-03 US disclosed
EP-2378878-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-10-26 EP disclosed
WO-2010077861-A1 INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-07-08 WO disclosed
US-20100152445-A1 Inhibitors of Diacylglycerol Acyltransferase MADRIGAL PHARMACEUTICALS, INC. 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152445-A1 Inhibitors of Diacylglycerol Acyltransferase DGAT2, DGAT1, ACAT2 TARBP2 2551/4885ALDH1A1 1249/4885KDM4E 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.